Dezerv

Fund Overview

Fund Size

Fund Size

₹639 Cr

Expense Ratio

Expense Ratio

0.21%

ISIN

ISIN

INF204KC1089

Minimum SIP

Minimum SIP

-

Exit Load

Exit Load

-

Inception Date

Inception Date

06 Jul 2021

About this fund

Nippon India Nifty Pharma ETF is a Sector - Healthcare mutual fund schemes offered by Nippon India Mutual Fund. This fund has been in existence for 2 years, 10 months and 12 days, having been launched on 06-Jul-21.
As of 17-May-24, it has a Net Asset Value (NAV) of ₹19.30, Assets Under Management (AUM) of 639.49 Crores, and an expense ratio of 0.21%.
  • Nippon India Nifty Pharma ETF has given a CAGR return of 10.74% since inception.
  • The fund's asset allocation comprises around 99.97% in equities, 0.00% in debts, and 0.03% in cash & cash equivalents.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+53.88%

+50.98% (Cat Avg.)

Since Inception

+10.74%

(Cat Avg.)

Portfolio Summaryas of 30th April 2024

Equity639.3 Cr99.97%
Others0.19 Cr0.03%

Top Holdings

All Holdings

Equity

Debt & Others

NameType sortAmount sortHoldings sort
Sun Pharmaceuticals Industries LtdEquity159.33 Cr24.92%
Dr Reddy's Laboratories LtdEquity74.23 Cr11.61%
Cipla LtdEquity72.18 Cr11.29%
Divi's Laboratories LtdEquity50.11 Cr7.84%
Lupin LtdEquity39.05 Cr6.11%
Aurobindo Pharma LtdEquity31.87 Cr4.98%
Alkem Laboratories LtdEquity23.84 Cr3.73%
Torrent Pharmaceuticals LtdEquity23.72 Cr3.71%
Zydus Lifesciences LtdEquity23.71 Cr3.71%
Ipca Laboratories LtdEquity17.69 Cr2.77%
Laurus Labs LtdEquity17.39 Cr2.72%
Mankind Pharma LtdEquity16.75 Cr2.62%
Glenmark Pharmaceuticals LtdEquity15.53 Cr2.43%
Abbott India LtdEquity13.81 Cr2.16%
J.B. Chemicals & Pharmaceuticals LtdEquity13.36 Cr2.09%
Biocon LtdEquity13.03 Cr2.04%
Gland Pharma LtdEquity11.63 Cr1.82%
Natco Pharma LtdEquity9.09 Cr1.42%
Sanofi India LtdEquity7.35 Cr1.15%
Granules India LtdEquity5.64 Cr0.88%
Triparty RepoCash - Repurchase Agreement0.35 Cr0.05%
Net Current AssetsCash-0.16 Cr0.03%
Cash Margin - CcilCash - Collateral0 Cr0.00%

Allocation By Market Cap (Equity)

Large Cap Stocks

61.97%

Mid Cap Stocks

30.03%

Small Cap Stocks

7.97%

Other Allocation

Equity Sector

Debt & Others

SectorAmount sortHoldings sort
Healthcare639.3 Cr99.97%

Risk & Performance Ratios

Standard Deviation

This fund

--

Cat. avg.

14.57%

Lower the better

Sharpe Ratio

This fund

--

Cat. avg.

0.69

Higher the better

Sortino Ratio

This fund

--

Cat. avg.

1.16

Higher the better

Fund Managers

Himanshu Mange

Himanshu Mange

Since December 2023

Additional Scheme Detailsas of 30th April 2024

ISININF204KC1089Expense Ratio0.21%Exit Load-Fund Size₹639 CrAge06 Jul 2021Lumpsum Minimum-Fund StatusOpen Ended Investment CompanyBenchmarkNifty Pharma TR INR

Investment ObjectiveInvestment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Withdrawal within 1 year

Flat 15% tax on realised gains (STCG - short term capital gains)

Withdrawal after 1 year

10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)

Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund nameExpense RatioExit LoadFund size
1Y
Motilal Oswal S&P BSE Healthcare ETF

Very High Risk

0.2%-₹13.07 Cr54.0%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

Very High Risk

1.0%1.0%₹694.50 Cr57.4%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹694.50 Cr55.3%
Aditya Birla Sun Life Nifty Healthcare ETF

Very High Risk

0.2%-₹36.50 Cr52.9%
ITI Pharma and Healthcare Fund Direct Growth

Very High Risk

0.4%1.0%₹161.86 Cr48.4%
ITI Pharma and Healthcare Fund Regular Growth

Very High Risk

2.3%1.0%₹161.86 Cr45.4%
Mirae Asset Healthcare Fund Direct Growth

Very High Risk

0.5%1.0%₹2236.01 Cr52.1%
Mirae Asset Healthcare Fund Regular Growth

Very High Risk

2.0%1.0%₹2236.01 Cr49.9%
Nippon India Nifty Pharma ETF

Very High Risk

0.2%-₹639.49 Cr53.9%
Axis NIFTY Healthcare ETF

Very High Risk

0.3%-₹16.41 Cr51.7%

About the AMC

Total AUM

₹4,54,004 Cr

Address

4th Floor, Tower A, Peninsula Business Park, Mumbai, 400 013

Other Funds by Nippon India Mutual Fund

Fund nameExpense RatioExit LoadFund size
1Y
Nippon India Fixed Maturity Plan - XLVI - Series 1 - 92 Days Direct Growth

Moderately High risk

-0.0%--
Nippon India Innovation Fund Direct Growth

Very High Risk

0.8%1.0%₹1454.62 Cr-
Nippon India Fixed Horizon Fund XLII Series 1 Direct Growth

Moderate Risk

----
Nippon India Fixed Horizon Fund XLII Series 7 Direct Growth

Moderate Risk

----
Nippon India Fixed Horizon Fund XLI Series 6 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund XLII Series 5 Direct Growth

Moderate Risk

----
Nippon India Fixed Horizon Fund XLI Series 7 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund - XLIII - Series 4 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund XLII Series 6 Direct Growth

Moderate Risk

----
Nippon India Interval Fund Quarterly Series I Direct Growth

Low Risk

-0.0%₹52.30 Cr7.0%
Nippon India Fixed Horizon Fund XXXX Series 10 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund XLIV Series 4 Direct Growth

Low to Moderate Risk

---6.8%
Nippon India Fixed Horizon Fund XLIV Series 3 Direct Growth

Moderate Risk

----
Nippon India Interval Fund Annual Series I Direct Growth

Low Risk

-0.0%₹16.45 Cr7.1%
Nippon India Fixed Horizon Fund XLIV Series 5 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund - XLIII - Series 1 Direct Growth

Low to Moderate Risk

-0.0%₹186.11 Cr7.1%
Nippon India Fixed Horizon Fund XLIV Series 1 Direct Growth

Moderate Risk

-0.0%-6.8%
Nippon India Fixed Horizon Fund - XLIII - Series 3 Direct Growth

Moderate Risk

----
Nippon India Fixed Horizon Fund XLI Series 5 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund XLII Series 3 Direct Growth

Moderate Risk

----
Nippon India Fixed Horizon Fund XLIII Series 5 Direct Growth

Moderate Risk

-0.0%₹159.89 Cr6.9%
Nippon India Fixed Horizon Fund XXXIX Series 12 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund - XLIII - Series 2 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund XLI Series 3 Direct Growth

Moderate Risk

-0.0%--
Nippon India Capital Protection Oriented Fund II Plan A Direct Growth

Low Risk

--₹40.32 Cr9.7%
Nippon India Interval Fund Quarterly Series III Direct Growth

Low Risk

-0.0%₹4.95 Cr7.1%
Nippon India Fixed Horizon Fund XLI Series 13 Direct Growth

Moderate Risk

----
Nippon India Fixed Horizon Fund XXXX Series 9 Direct Growth

Moderate Risk

-0.0%--
Nippon India Interval Fund Quarterly Series II Direct Growth

Moderate Risk

-0.0%₹83.40 Cr7.4%
Nippon India Fixed Horizon Fund XXXX Series 18 Direct Growth

Moderate Risk

-0.0%--
Nippon India Interval Fund Monthly Series II Direct Growth

Low Risk

-0.0%₹3.95 Cr6.4%
Nippon India Fixed Horizon Fund XXXX Sr 20 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund - XXXX Series 13 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund - XLV - Series 4 Direct Growth

Low to Moderate Risk

-0.0%-6.8%
Nippon India Fixed Horizon Fund XLI Series 9 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund XLI Series 8 Direct Growth

Moderate Risk

-0.0%₹58.95 Cr7.0%
Nippon India Interval Fund Monthly Series I Direct Growth

Low Risk

-0.0%₹3.22 Cr6.3%
Nippon India Fixed Horizon Fund - XLV - Series 5 Direct Growth

Moderately High risk

-0.0%-8.8%
Nippon India Fixed Horizon Fund XXXIX Series 13 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund XLII Series 2 Direct Growth

Moderate Risk

----
Nippon India Nifty SDL Plus G-Sec - Jun 2029 Maturity 70:30 Index Fund Direct Growth

Moderate Risk

0.2%0.0%₹247.60 Cr6.7%
Nippon India Arbitrage Fund Direct Growth

Low Risk

0.4%0.0%₹14796.07 Cr8.4%
Nippon India Gilt Securities Fund Direct Growth

Moderate Risk

0.5%0.0%₹1867.36 Cr7.0%
Nippon India Banking & Financial Services Fund Direct Growth

Very High Risk

1.1%1.0%₹5541.72 Cr26.3%
Nippon India Power & Infra Fund Direct Growth

Very High Risk

1.2%1.0%₹5043.02 Cr82.0%
Nippon India Dynamic Bond Fund Direct Growth

Moderate Risk

0.3%0.0%₹4554.19 Cr6.6%
Nippon India Growth Fund Direct Growth

Very High Risk

0.8%1.0%₹26821.89 Cr60.1%
Nippon India Multi Cap Fund Direct Growth

Very High Risk

0.8%1.0%₹30500.56 Cr54.2%
Nippon India Gold Savings Fund Direct Growth

High Risk

0.9%1.0%₹1842.45 Cr19.9%
Nippon India Floating Rate Fund Direct Growth

Moderate Risk

0.3%0.0%₹7946.15 Cr7.5%

Risk Level

Your principal amount will be at Very High Risk

Very High Risk
Wealth Monitor

Unlock Expert Insights!

Maximise Returns with our Wealth Monitor App. Try it now!

Still got questions?
We're here to help.

The NAV of Nippon India Nifty Pharma ETF, as of 17-May-2024, is ₹19.30.
The fund's allocation of assets is distributed as 99.97% in equities, 0.00% in bonds, and 0.03% in cash and cash equivalents.
The fund managers responsible for Nippon India Nifty Pharma ETF are:-
  1. Himanshu Mange